Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation

• Published in: Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 775 - 30
• Main Authors: Adigweme, Ikechukwu, Akpalu, Edem, Yisa, Mohammed, Donkor, Simon, Jarju, Lamin B, Danso, Baba, Mendy, Anthony, Jeffries, David, Njie, Abdoulie, Bruce, Andrew, Royals, Michael, Goodson, James L, Prausnitz, Mark R, McAllister, Devin, Rota, Paul A, Henry, Sebastien, Clarke, Ed
• Format: Journal Article
• Language: English
• Published: England BioMed Central 14.09.2022; BMC
• Subjects: Adolescent; Adult; Antibodies; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Congenital diseases; Disease control; Displaced persons; Double dummy; Double-Blind Method; Double-blind studies; Fatalities; Gambia; Glycoproteins; Hearing loss; Humans; Infant; Infections; Measles; Measles - prevention & control; Measles vaccine; Measles Vaccine - adverse effects; Microarray patch; Microneedle; Microneedle patch; Pediatrics; Population density; Proteins; Randomized Controlled Trials as Topic; Rubella; Rubella - prevention & control; Rubella vaccine; Rubella Vaccine - adverse effects; Study Protocol; Vaccines; Viral infections; Young Adult; Gambia; Atlanta Georgia; Georgia; United States > US; Microarray patch; Age de-escalation; Measles vaccine; Phase 2 clinical trial; Rubella vaccine; Phase 1 clinical trial; Double dummy; Microneedle; Microneedle patch
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-022-06493-5

New strategies to increase measles and rubella vaccine coverage, particularly in low- and middle-income countries, are needed if elimination goals are to be achieved. With this regard, measles and rubella vaccine microneedle patches (MRV-MNP), in which the vaccine is embedded in dissolving microneedles, offer several potential advantages over subcutaneous delivery. These include ease of administration, increased thermostability, an absence of sharps waste, reduced overall costs and pain-free administration. This trial will provide the first clinical trial data on MRV-MNP use and the first clinical vaccine trial of MNP technology in children and infants. This is a phase 1/2, randomized, active-controlled, double-blind, double-dummy, age de-escalation trial. Based on the defined eligibility criteria for the trial, including screening laboratory investigations, 45 adults [18-40 years] followed by 120 toddlers [15-18 months] and 120 infants [9-10 months] will be enrolled in series. To allow double-blinding, participants will receive either the MRV-MNP and a placebo (0.9% sodium chloride) subcutaneous (SC) injection or a placebo MNP and the MRV by SC injection (MRV-SC). Local and systemic adverse event data will be collected for 14 days following study product administration. Safety laboratories will be repeated on day 7 and, in the adult cohort alone, on day 14. Unsolicited adverse events including serious adverse events will be collected until the final study visit for each participant on day 180. Measles and rubella serum neutralizing antibodies will be measured at baseline, on day 42 and on day 180. Cohort progression will be dependent on review of the unblinded safety data by an independent data monitoring committee. This trial will provide the first clinical data on the use of a MNP to deliver the MRV and the first data on the use of MNPs in a paediatric population. It will guide future product development decisions for what may be a key technology for future measles and rubella elimination. Pan-African Clinical Trials Registry 202008836432905 . gov NCT04394689.